BiotechTube
Home/Pipeline/FMC

FMC

Endometriosis

Pre-clinicalActive

Key Facts

Indication
Endometriosis
Phase
Pre-clinical
Status
Active
Company
FimmCyte

About FimmCyte

FimmCyte AG is a pre-clinical, private biotech based in Zurich/Basel, Switzerland, developing a novel immunotherapy platform targeting fibrosis. Its lead candidate, FMC, is designed for endometriosis, with potential expansion into other fibro-inflammatory conditions like kidney and heart disease. The company has garnered recognition in the Swiss startup ecosystem and secured strategic partnerships and non-dilutive funding to advance its pipeline.

View full company profile

Therapeutic Areas

EndometriosisFibro-inflammatory Diseases

Other Endometriosis Drugs

DrugCompanyPhase
Promarker™EndoProteomics InternationalLate‑stage validation
EV‑EndoCarthericsPreclinical
Endometriosis ProgramCyclana BioDiscovery
Endometriosis Genetic StudyJuneau BiosciencesDiscovery
Potential Diagnostic DevelopmentJuneau BiosciencesResearch
Endometriosis Discovery ProgramMetri BioDiscovery
Endometriosis Test SuiteHeranova LifesciencesPre-clinical
EndomTestKephera DiagnosticsCommercial (LDT)
ENDO-205EndoCyclic TherapeuticsPhase 1
Undisclosed ImmunotherapyApheon BiosciencePreclinical
ABC-201AbcelyPreclinical
ERβ Modulator ProgramCadenza BioPreclinical